Robert M Carey1. 1. Division of Endocrinology and Metabolism, Department of Medicine, University of Virginia Health System, Charlottesville, Virginia, USA.
Abstract
PURPOSE OF REVIEW: This review updates major new findings and concepts introduced during the past year on the role of angiotensin II (Ang II) subtype 2 receptors (AT2Rs) in the control of blood pressure and renal function. RECENT FINDINGS: AT2R activation prevents sodium (Na) retention and lowers blood pressure in the Ang II infusion model of experimental hypertension and prevents salt-sensitive hypertension in the obese Zucker rat model of obesity and the metabolic syndrome. Ang II metabolite, des-aspartyl-Ang II (Ang III) is the predominant AT2R agonist in the kidney and possibly also in the vasculature; a novel synthetic Ang III peptide, β-Pro-Ang III, is vasodepressor and lowers blood pressure in conscious spontaneously hypertensive rats in the presence of low-level Ang II type 1 receptor (AT1R) blockade. Because nitric oxide is a product of AT2R activation, a potential feed-forward loop, wherein nitric oxide increases AT2R transcription, may reinforce the beneficial actions of AT2R in the long term. AT2R activation also reduces proteinuria and oxidative stress in glomerulosclerotic kidneys of high-salt obese Zucker rats. SUMMARY: Studies during the past year have helped to clarify the physiological and pathophysiological roles of AT2Rs and have enhanced the promise of AT2R agonists in cardiovascular and renal disease.
PURPOSE OF REVIEW: This review updates major new findings and concepts introduced during the past year on the role of angiotensin II (Ang II) subtype 2 receptors (AT2Rs) in the control of blood pressure and renal function. RECENT FINDINGS:AT2R activation prevents sodium (Na) retention and lowers blood pressure in the Ang II infusion model of experimental hypertension and prevents salt-sensitive hypertension in the obese Zucker rat model of obesity and the metabolic syndrome. Ang II metabolite, des-aspartyl-Ang II (Ang III) is the predominant AT2R agonist in the kidney and possibly also in the vasculature; a novel synthetic Ang III peptide, β-Pro-Ang III, is vasodepressor and lowers blood pressure in conscious spontaneously hypertensiverats in the presence of low-level Ang II type 1 receptor (AT1R) blockade. Because nitric oxide is a product of AT2R activation, a potential feed-forward loop, wherein nitric oxide increases AT2R transcription, may reinforce the beneficial actions of AT2R in the long term. AT2R activation also reduces proteinuria and oxidative stress in glomerulosclerotic kidneys of high-saltobese Zucker rats. SUMMARY: Studies during the past year have helped to clarify the physiological and pathophysiological roles of AT2Rs and have enhanced the promise of AT2R agonists in cardiovascular and renal disease.
Authors: Shetal H Padia; Brandon A Kemp; Nancy L Howell; Susanna R Keller; John J Gildea; Robert M Carey Journal: Hypertension Date: 2011-12-27 Impact factor: 10.190
Authors: Emma S Jones; Antony Vinh; Claudia A McCarthy; Tracey A Gaspari; Robert E Widdop Journal: Pharmacol Ther Date: 2008-08-31 Impact factor: 12.310
Authors: Diego T Quiroga; Johanna G Miquet; Lorena Gonzalez; Ana I Sotelo; Marina C Muñoz; Pedro M Geraldes; Jorge F Giani; Fernando P Dominici Journal: Mol Cell Endocrinol Date: 2019-09-17 Impact factor: 4.102
Authors: Fernando P Dominici; Luciana C Veiras; Justin Z Y Shen; Ellen A Bernstein; Diego T Quiroga; Ulrike M Steckelings; Kenneth E Bernstein; Jorge F Giani Journal: Br J Pharmacol Date: 2020-09-13 Impact factor: 8.739